Regeneron Pharmaceuticals (REGN)
$706.94
16.53 (2.28%)
REGN Stock Quote Delayed 30 Minutes
7 Best Stocks to Buy Until the Next Seismic Shift
No company can guarantee its future, but here are some that are well-positioned to take advantage of current trends.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
64.88B
PE Ratio
18.44
EPS
38.33
Volume (Avg. Vol.)
713,051
Day's Range
$701.07 - $721.41
52-Week Range
$642.00 - $1,211.20
Dividend & Yield
N/A (N/A)
REGN Stock Predictions, Articles, and Regeneron Pharmaceuticals News
Value Investors Should Buy into the Teva Stock Dip
Teva stock is now at yearly lows, a victim of negative macro news, falling stock markets, and year-end tax-loss selling.
Biogen Stock Rebounds After Impressive Q3 Earnings
Biogen stock reaffirmed its dominance in MS and the neurosciences market. At a low P/E mutliple, investors should look at BIIB again.
3 Big Stock Charts for Friday: Sherwin-Williams, Regeneron and Allstate
These three stock charts have the makings and markings of trade set-ups. Here's why, and how to best play them in this unusual environment.
The Bull Case for Regeneron Pharmaceuticals Inc Couldn’t Be More Clear
Regeneron trades at just 25.5 times earnings, despite 20% growth and an ability to bring as much as one-third of revenue to the bottom line. With pharma no longer out of fashion, buy REGN stock before the market pushes it higher.
Tread Very Carefully When Investing in AnaptysBio Inc
ANAB is up on positive clinical studies posted in the last few months. But the small sample size and risks ahead could hurt the stock in the near term.
9 More Stocks Still Growing Faster Than Amazon
If you're looking for growth, Amazon.com isn't your only investment choice. These names are on a tear as well, and could be worthy additions to your portfolio.
Lackluster Quant Score Penalize Regeneron Pharmaceuticals (REGN) Rating
Portfolio Grader currently ranks Regeneron Pharmaceuticals Inc (NASDAQ:REGN) a Hold. The methods for investing incorporated in this analytical tool developed by Louis Navellier evaluates and ranks nearly 5,000 stocks each week from a fundamental and quantitative perspective. This represents no change from the previous week and is the same ranking REGN has had from Portfolio Grader for 6 months.
Sector ETF and Stock Winners in the 10 Years Since the Great Recession
While most of the sectors have flourished over the past decade, consumer discretionary and information technology have led the way .
Regeneron Pharmaceuticals (REGN) a Hold on Vapid Quant Score
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is classified as a component of the 350 company Biotechnology GICS industry group, which is part of the 782 company GICS Health Care sector. REGN's market value is $40.1 billion which places it in the top decile in its industry group. The current Portfolio Grader ranking for REGN puts it 188 among the 350 companies in this industry group, giving it a lower than average position; in the third quartile of the sector with a ranking of 428 among the 782 companies in the sector, and number 2,601 in the nearly 5,000 company Portfolio Grader universe.
Regeneron Pharmaceuticals (REGN) a Hold on Uninspiring Industry Group Rank
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is ranked as a Hold using the Portfolio Grader stock evaluator of Louis Navellier, which incorporates his investing approach. This represents no change from the previous week and is the same ranking REGN has had from Portfolio Grader for 5 months.
Regeneron Pharmaceuticals (REGN) a Hold on Poor Industry Group Rank
Portfolio Grader currently ranks Regeneron Pharmaceuticals Inc (NASDAQ:REGN) a Hold. With proprietary fundamental and quantitative analytical tools developed by Louis Navellier, this analytical tool evaluates nearly 5,000 stocks weekly. This represents no change from the previous week and is the same ranking REGN has had from Portfolio Grader for 5 months.
Weak Quant Score Restrict Regeneron Pharmaceuticals (REGN) Rating
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is one of 349 companies within the Biotechnology GICS industry group, which is in turn part of the 782 company GICS Health Care sector. REGN has a market value of $43.4 billion which is in the top 10% of its industry group. The ranking for REGN by Portfolio Grader places it 173 among the 349 companies in this industry group, giving it an above-average position; in the third quartile of the sector with a ranking of 404 among the 782 companies in the sector, and number 2,615 in the nearly 5,000 company Portfolio Grader universe.
